Core Insights - Lifeward is positioning itself as a MedTech platform with a clear path to profitability and long-term Biotech potential through a strategic partnership with Oramed Pharmaceuticals [1][2] Investment and Financial Structure - Lifeward will receive up to $47 million in strategic investment from Oramed and another investor, which includes equity, convertible notes, milestone-based funding, and warrant coverage [2][14] - The investment structure aims to support Lifeward's journey to profitability while allowing for selective investments in high-value innovations [2] Technology Acquisition - Lifeward is acquiring Oramed's Protein Oral Delivery (POD™) technology, which targets the $600+ billion injectable drugs market, including the potential for ORMD-0801 to become the first commercialized oral insulin [1][3] - The POD™ technology is designed to transform injectable biological therapies into oral medications, addressing a significant market opportunity in diabetes and other metabolic diseases [3][10] Clinical Development and Management - Oramed will manage and fund the clinical development of the POD™ technology, allowing Lifeward to focus on profitability and cash generation while retaining exposure to biotech opportunities [4][8] - The POD™ technology has shown promise in clinical trials, with the lead drug candidate ORMD-0801 achieving significant results in reducing HbA1c levels [12] Strategic Goals and Diversification - The partnership with Oramed marks the beginning of Lifeward's broader diversification strategy across medical technology and biotechnology [5] - Lifeward aims to achieve sustainable profitability from existing FDA-approved products while building a balanced biomedical portfolio that combines near-term revenue with long-term biotech innovation [6][7]

Core Viewpoint - The strategic transaction between Oramed Pharmaceuticals and Lifeward involves the transfer of Oramed's proprietary Protein Oral Drug (POD™) delivery technology to Lifeward, positioning Oramed as a significant shareholder with a 49.9% beneficial ownership interest in Lifeward [2][3][4] Transaction Overview - Oramed will transfer its POD™ technology to Lifeward, which will result in Oramed obtaining a 49.9% beneficial ownership interest in Lifeward, along with warrants [5][6] - Lifeward will issue $10 million in senior secured convertible notes in a private placement, with Oramed investing $9 million, and an additional milestone-based $10 million note, also with Oramed investing $9 million, both having 100% warrant coverage [2][14] Strategic Vision - The transaction is seen as a strategic evolution for Oramed, allowing it to maintain exposure to oral drug delivery innovation while participating in a medical robotics company poised for significant growth [3][4] - Lifeward's acquisition of the POD™ technology is expected to enhance its capabilities in advancing oral insulin programs and diversifying its biomedical innovation portfolio [4][6] Leadership and Management - Lifeward's leadership under President and CEO Mark Grant, who has over 25 years of experience in healthcare and medical technology, is expected to drive the advancement of the newly acquired oral drug delivery platform [4][6] - Oramed will manage the upcoming anticipated clinical trial related to the POD™ technology [3][7] Financial Performance - Lifeward's FDA-approved products, ReWalk® and AlterG®, generated $26 million in revenue over the last four quarters, indicating a solid financial foundation for the company [6]